At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 426 enrolled
Drug / intervention
A-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
In Brief
A Phase 3 clinical trial evaluating A-101 for Common Wart. Completed, enrolled 426 participants across 46 sites.
Detailed Summary
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJan 23, 2019
Enrollment StartFeb 7, 2019
Primary CompletionNov 27, 2019
Study CompletionDec 20, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.4 years ago
Interventions
A-101drug
hydrogen peroxide topical solution 45%